

**2<sup>nd</sup> September 2009**

**REGEN THERAPEUTICS PLC**  
(“ReGen” or the “Company”; Ticker: (RGT))

**TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES**

|                                                                                                                 |                                                    |
|-----------------------------------------------------------------------------------------------------------------|----------------------------------------------------|
| 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii): | <b>ReGen Therapeutics Plc</b>                      |
| 2. Reason for the notification:                                                                                 | <b>An acquisition or disposal of voting rights</b> |
| 3. Full name of person(s) subject to the notification obligation (iii):                                         | <b>Barclays PLC</b>                                |
| 4. Full name of shareholder(s) (if difference from 3):                                                          | <b>Barclays Stockbrokers Ltd</b>                   |
| 5. Date of the transaction and date on which the threshold is crossed or reached (v):                           | <b>27<sup>th</sup> August 2009</b>                 |
| 6. Date on which issuer notified:                                                                               | <b>1<sup>st</sup> September 2009</b>               |
| 7. Threshold(s) that is/are crossed or reached:                                                                 | <b>13% to 14%</b>                                  |
| 8. Notified details                                                                                             |                                                    |
| A: Voting rights attached to shares                                                                             |                                                    |
| Class/type of share if possible using the ISIN Code                                                             | <b>GB00B28XMY25</b>                                |
| Situation Previous to the triggering transaction (vi) –<br>Number of Shares                                     | <b>4,137,087</b>                                   |
| Number of Voting Rights (viii)                                                                                  | <b>4,137,087</b>                                   |
| Resulting situation after the triggering transaction (viii) –<br>Number of Shares                               | <b>4,436,790</b>                                   |
| Number of Voting Rights – Direct (x)                                                                            | <b>N/A</b>                                         |
| Number of Voting Rights – Indirect (xi)                                                                         | <b>4,436,790</b>                                   |
| % of voting rights – Direct                                                                                     | <b>N/A</b>                                         |
| % of voting rights – Indirect                                                                                   | <b>14.21</b>                                       |
| B: Financial Instruments                                                                                        |                                                    |
| Resulting situation after the triggering transaction (xii)                                                      |                                                    |
| Type of financial instrument                                                                                    | <b>N/A</b>                                         |
| Expiration date (xiii)                                                                                          | <b>N/A</b>                                         |
| Exercise/Conversion Period/Date (xiv)                                                                           | <b>N/A</b>                                         |
| Number of voting rights that may be acquired if the instrument is exercised/converted                           | <b>N/A</b>                                         |
| % of voting rights                                                                                              | <b>N/A</b>                                         |
| C: Financial Instruments with similar economic effect to Qualifying Financial Instruments                       |                                                    |

Resulting situation after the triggering transaction

|                              |     |
|------------------------------|-----|
| Type of financial instrument | N/A |
| Exercise Price               | N/A |
| Experation Date              | N/A |
| Number of voting rights      | N/A |
| Instrument refers to         |     |
| % of voting rights           | N/A |

Total (A+B+C)

|                         |           |
|-------------------------|-----------|
| Number of voting rights | 4,436,790 |
| % of voting rights      | 14.21     |

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv):

**Barclays Stockbrokers Ltd**

Proxy Voting:

|                                                                  |                      |
|------------------------------------------------------------------|----------------------|
| 10. Name of the proxy holder:                                    | N/A                  |
| 11. Number of voting rights proxy holder will cease to hold:     | N/A                  |
| 12. Date on which proxy holder will cease to hold voting rights: | N/A                  |
| 13. Additional information:                                      | N/A                  |
| 14. Contact name:                                                | <b>Geoff Smith</b>   |
| 15. Contact telephone number:                                    | <b>0207 116 2913</b> |

**For further information:**

For further information, please contact:

Percy Lomax  
ReGen Therapeutics Plc  
Tel: 020 7153 4920

Roland Cornish/Felicity Geidt  
Beaumont Cornish Limited  
Tel: 020 7628 3396